YPB does real deals worth $26M to supply anti-counterfeit technology
Australian anti-counterfeiting technology developer YPB Group Ltd (ASX:YPB) has signed two agreements with two of China’s largest bottle closure and ink manufacturers to protect their products with its invisible tracer technology.
The deal with Hicap Closures Ltd. (Hicap) will see YPB supply its invisible anti-counterfeit tracer products and T1 scanner system over an exclusive four-year period, projected to bring in AUD$10M in revenue.
YPB has also signed a five-year agreement with Shenzen Shensaier, a Chinese company that supplies high end inks to tobacco and wine brands. The agreement could be worth AUD$16M based on projected revenues.
Counterfeit problems – and YPB’s solution
Counterfeit goods are a global problem estimated to cost over $1.7 trillion dollars in lost revenue for manufacturers and retailers. This has led to the rise of an anti-counterfeiting industry that aims to put a stop the production, sale and distribution of fake products. YPB is aiming to become a market leader in providing technological solutions.
YPB has developed invisible tracers made from rare earth materials that can be attached to any product or packaging to serve as a signal that identifies it as the genuine article.
YPB has also developed a range of hand held scanners that can detect the tracers, and is also building a mobile app called Brand Reporter that puts the power to detect invisible tracers in the hands of consumers.
Deals to bring YPB revenue of up to AUD$26M
Hicap makes up to two billion bottle closures every year that are sold around the world, including to the Australian wine group Peter Lehman, as well as food and pharmaceutical clients.
However, counterfeit bottles and products are a growing problem, and to blunt their effect Hicap will include YPB’s invisible tracer products into bottle closures it manufacturers – to protect consumers and company reputations.
Hicap will also take delivery of YPB’s T1 scanners, the first generation of the product, which can be used to detect the tracers within the closures.
The agreement came after Hicap conducted a trial period of YPB’s anti-counterfeiting technologies in which they were tested in the factory and the field. The tracers and scanners will now be integrated with Hicap’s products manufactured by four subsidiary companies across China.
Meanwhile, Shenzen Shensaier will incorporate YPB’s invisible tracers into the high-end inks it supplies to tobacco and wine manufacturers in China.
YPB’s Executive Chairman and CEO John Houston says the deals place the company firmly at the centre of China’s growing anti-counterfeiting industry. “The projected growth and infrastructure investment being made by Hicap Closures combined with their market position and their vision to adopt YPB’s technology offers YPB access to this key high volume industry,” he says.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.